Tyche Industries Ltd
Incorporated in 1998, Tyche Industries Ltd
does manufacturing of active pharmaceutical ingredients[1]
- Market Cap ₹ 225 Cr.
- Current Price ₹ 220
- High / Low ₹ 230 / 158
- Stock P/E 15.8
- Book Value ₹ 118
- Dividend Yield 0.91 %
- ROCE 17.4 %
- ROE 12.9 %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
Cons
- The company has delivered a poor sales growth of 7.88% over past five years.
- Dividend payout has been low at 7.20% of profits over last 3 years
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
49 | 78 | 104 | 64 | 54 | 43 | 52 | 54 | 74 | 78 | 62 | 75 | 81 | |
43 | 68 | 94 | 57 | 51 | 37 | 43 | 45 | 52 | 54 | 51 | 59 | 65 | |
Operating Profit | 6 | 10 | 11 | 7 | 3 | 6 | 9 | 9 | 21 | 25 | 11 | 16 | 16 |
OPM % | 13% | 13% | 10% | 11% | 5% | 14% | 18% | 17% | 29% | 32% | 18% | 21% | 20% |
0 | 1 | 0 | 0 | 2 | 2 | 2 | 3 | 4 | 4 | 3 | 5 | 5 | |
Interest | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Depreciation | 1 | 1 | 1 | 3 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
Profit before tax | 4 | 9 | 8 | 3 | 3 | 6 | 9 | 10 | 23 | 27 | 13 | 19 | 19 |
Tax % | 31% | 33% | 32% | 33% | 4% | 48% | 34% | 27% | 25% | 25% | 26% | 26% | |
3 | 6 | 6 | 2 | 2 | 3 | 6 | 7 | 18 | 20 | 9 | 14 | 14 | |
EPS in Rs | 2.77 | 5.94 | 5.39 | 1.88 | 2.41 | 3.00 | 5.72 | 6.98 | 17.13 | 19.49 | 9.10 | 13.82 | 13.89 |
Dividend Payout % | 18% | 8% | 9% | 26% | 21% | 17% | 9% | 7% | 0% | 5% | 16% | 0% |
Compounded Sales Growth | |
---|---|
10 Years: | 0% |
5 Years: | 8% |
3 Years: | 1% |
TTM: | 21% |
Compounded Profit Growth | |
---|---|
10 Years: | 9% |
5 Years: | 19% |
3 Years: | -7% |
TTM: | 14% |
Stock Price CAGR | |
---|---|
10 Years: | 25% |
5 Years: | 26% |
3 Years: | -5% |
1 Year: | 18% |
Return on Equity | |
---|---|
10 Years: | 14% |
5 Years: | 16% |
3 Years: | 15% |
Last Year: | 13% |
Balance Sheet
Figures in Rs. Crores
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Sep 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 |
Reserves | 23 | 28 | 33 | 34 | 35 | 38 | 43 | 50 | 67 | 86 | 94 | 107 | 110 |
9 | 11 | 11 | 9 | 11 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
11 | 39 | 19 | 12 | 11 | 13 | 14 | 14 | 18 | 21 | 16 | 24 | 15 | |
Total Liabilities | 54 | 88 | 74 | 64 | 67 | 61 | 67 | 74 | 95 | 117 | 120 | 141 | 136 |
22 | 28 | 33 | 29 | 28 | 27 | 20 | 19 | 18 | 18 | 17 | 17 | 17 | |
CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
31 | 60 | 40 | 35 | 39 | 34 | 47 | 55 | 77 | 98 | 104 | 125 | 119 | |
Total Assets | 54 | 88 | 74 | 64 | 67 | 61 | 67 | 74 | 95 | 117 | 120 | 141 | 136 |
Cash Flows
Figures in Rs. Crores
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
2 | 3 | 9 | 2 | 12 | 11 | 5 | 4 | 15 | 15 | 4 | 7 | |
-2 | -6 | -6 | -1 | -1 | 1 | 6 | 1 | 2 | 0 | 3 | 2 | |
-3 | 2 | 0 | -3 | 2 | -11 | -1 | -0 | -1 | -1 | -1 | -2 | |
Net Cash Flow | -2 | -1 | 3 | -2 | 12 | 1 | 11 | 4 | 17 | 15 | 7 | 7 |
Ratios
Figures in Rs. Crores
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 101 | 149 | 46 | 91 | 107 | 81 | 68 | 69 | 64 | 80 | 96 | 107 |
Inventory Days | 156 | 168 | 91 | 138 | 68 | 84 | 85 | 123 | 122 | 148 | 148 | 195 |
Days Payable | 93 | 265 | 68 | 76 | 93 | 130 | 87 | 96 | 91 | 93 | 78 | 134 |
Cash Conversion Cycle | 164 | 52 | 69 | 153 | 82 | 34 | 67 | 96 | 94 | 135 | 167 | 168 |
Working Capital Days | 127 | 100 | 68 | 122 | 89 | 60 | 67 | 87 | 77 | 83 | 121 | 127 |
ROCE % | 13% | 22% | 18% | 7% | 5% | 12% | 18% | 17% | 34% | 32% | 13% | 17% |
Documents
Announcements
-
Compliance Certificate For The Financial Year Ended March 31, 2024
15 Apr - Compliance Certificate U/R 7(3) of SEBI (LODR) Regulations 2015.
- Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A 15 Apr
- Certificate U/R 40(9) Of SEBI(LODR) Regulations, 2015 For The Year Ended March 31, 2024 8 Apr
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
5 Apr - Certificate under Regulation 74(5) of the SEBI (D&P) Regulations 2018
- Closure of Trading Window 25 Mar
Annual reports
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
-
Financial Year 2008
from bse
Business Overview:[1]
Company is a manufacturer and exporter of APIs, Intermediates and Nutraceuticals. It is one of the largest Indian manufacturers of Glucosamine Hydrochloride and corresponding sodium and potassium salts which are mainly exported to USA and Europe